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ABSTRACT
Introduction: We compared insulin antibody
response (IAR) profiles in patients with type 1
diabetes (T1D) or type 2 diabetes (T2D) who
received LY2963016 insulin glargine (LY IGlar)
or Lantus insulin glargine (IGlar) and evalu-
ated the potential relationship between higher
IARs and clinical and safety outcomes with a
focus on patients who exhibited antibody
responses in the upper quartile.
Methods: Data from ELEMENT-1 (52-week
open-label in T1D) and ELEMENT-2 (24-week,
double-blind study in T2D) were analyzed.
Maximum postbaseline IAR levels and propor-
tions of patients in the upper quartile of maxi-
mum antibody percent binding (UQMAPB;
patients with maximum postbaseline percent
binding in the highest 25% of maximum values
observed) were compared for differential
treatment effects on clinical efficacy outcomes
and incidence of adverse events. Continuous
outcomes were analyzed by analysis of covari-
ance. Categorical data were analyzed by the
Cochran–Mantel–Haenszel or Breslow–Day test.
Results: In both studies (N = 532 evaluable
patients with T1D; N = 730 with T2D), no sta-
tistically significant differences between LY
IGlar and IGlar were observed for maximum
antibody percent binding (MAPB) levels or for
proportions of patients in the respective
UQMAPB. No statistically significant differen-
tial treatment effects were observed in the rela-
tionship between MAPB and clinical efficacy
and safety outcomes.
Conclusions: Maximum postbaseline IAR levels
and the proportion of patients with high IAR
levels were similar for LY IGlar and IGlar. High
antibody levels did not affect clinical outcomes.
These results add further evidence supporting
similar IARs of LY IGlar and IGlar.
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INTRODUCTION
LY2963016 insulin glargine (LY IGlar; Eli Lilly
and Company, Indianapolis, IN, USA) is the first
biosimilar insulin approved in the European
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Union [1] and Japan in 2014 [2] and was
authorized as a follow-on biologic in the USA
[3]. LY2963016 insulin glargine and Lantus
insulin glargine (IGlar; recombinant DNA ori-
gin; Sanofi-Aventis, Paris, France) have identical
primary amino acid sequences, the same phar-
maceutical form and strength, and the phar-
macokinetic/pharmacodynamic, efficacy, and
safety profiles of LY IGlar are highly similar to
those of IGlar [4–7].
Insulin products can elicit the formation of
insulin antibodies, often without clinical con-
sequences [8, 9]. However, rare instances exist
where the presence of insulin antibodies may
have clinically relevant effects on efficacy and
safety [9–11]. We have previously shown that
the immunogenicity profile of LY IGlar is simi-
lar to that of IGlar [7], and that both LY IGlar
and IGlar have comparable insulin antibody
response (IAR) profiles, with no observed effect
on efficacy and safety outcomes [7]. While the
median antibody levels were low (i.e., less than
5%) and similar between treatment groups,
there was variation in patient-to-patient IARs
[7]. Because high IARs may provide additional
insight into potential immune-mediated effects
on efficacy or safety, and these effects may be
diluted by looking at all patients, this study
focuses on patients who elicited the highest
quartile of maximum IARs observed in the LY
IGlar phase 3 studies to determine how LY IGlar
and IGlar compared in this subgroup of patients
and assess whether their IARs were related to
clinical outcomes. Thus, we assessed and com-
pared IAR profiles of LY IGlar and IGlar treat-
ment in patients with type 1 diabetes mellitus
(T1D) or type 2 diabetes mellitus (T2D), assessed
the frequencies of higher IARs among patients
treated with either insulin glargine product, and
evaluated the potential relationship between
higher IARs and clinical and safety outcomes.
METHODS
Data from the ELEMENT-1 and ELEMENT-2
studies were analyzed. Both trials were regis-
tered at Clinical Trials.gov (NCT01421147 and
NCT01421459). Detailed study methods and
results for the primary endpoints for both
studies have been previously described [5, 6].
Briefly, ELEMENT-1 was a 52-week (24-week
treatment period plus 28-week extension per-
iod), open-label study of patients with T1D
being treated with basal and bolus insulin [5].
ELEMENT-2 was a 24-week, double-blind study
of patients with T2D who were insulin-naı¨ve or
previously treated with IGlar [6]. In both stud-
ies, patients were randomized to receive an LY
IGlar or IGlar dose that was equivalent to their
prestudy insulin dose except for patients with
T2D who were insulin-naı¨ve and started with
10 units of LY IGlar or IGlar. The LY IGlar or
IGlar dose was titrated on the basis of daily
blood glucose levels [5, 6]. The primary efficacy
outcome in both studies was to demonstrate the
non-inferiority (0.4% and then 0.3% margin) of
LY IGlar to IGlar as measured by change in
HbA1c from baseline to 24 weeks [5, 6]. Both of
these studies were done in accordance with the
International Conference on Harmonisation
Guidelines for Good Clinical Practice and the
Declaration of Helsinki [12], and written
informed consent was obtained from all
patients [5, 6].
Antibody determination methods have been
described in greater detail previously [5–7].
Briefly, samples used in this study for antibody
determination were those collected before ran-
domization (baseline) and at study endpoint.
Insulin antibodies were quantified as percent
binding using a classic radioimmunoassay for-
mat. The anti-LY IGlar antibody assay has
cross-reactivity to IGlar and human insulin;
hence, antibodies to LY IGlar and IGlar were
measured using the same assay [5–7]. Insulin
antibody testing was conducted by Millipore
(St. Charles, MO, USA).
In each study, patients in the upper quartile
of maximum antibody percent binding
(UQMAPB) were determined as follows: among
all patients with postbaseline insulin antibod-
ies, the maximum postbaseline insulin antibody
level (percent binding) per patient was identi-
fied. Patients whose maximum postbaseline
percent binding belonging to the highest 25%
of the maximum values observed comprised the
UQMAPB. Patients in the lower 75% and
patients who did not have any detectable anti-
bodies postbaseline comprised those patients
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not in the UQMAPB. Postbaseline maximum
antibody percent binding (MAPB) levels and the
proportions of patients who exhibited IARs in
the UQMAPB with either treatment were eval-
uated to compare the IAR profiles of LY IGlar
and IGlar. Separate analyses for each study also
compared LY IGlar to IGlar for clinical out-
comes [changes in glycated hemoglobin
(HbA1c) (%), basal insulin dose (U/kg/day),
weight (kg), incidence of adverse events, and
incidence of total hypoglycemia] among
patients who did or did not exhibit IARs in the
UQMAPB. The potential differential treatment
effects of UQMAPB status on clinical and safety
outcomes were also assessed by interaction
tests. Hypoglycemia was defined in accordance
with American Diabetes Association [13] and
European Medicine Agency [14] guidelines as
having a blood glucose no greater than
3.9 mmol/L (70 mg/dL) or signs or symptoms
attributable to low blood glucose levels. Analy-
ses were also performed with hypoglycemia
defined as having a blood glucose of less than
3.0 mmol/L (54 mg/dL), a cutoff that had been
recommended in the past [15].
Statistical Analysis
The analysis population was comprised of all
randomized patients who took at least one dose
of study drug (full analysis set) and also had a
baseline and at least one postbaseline insulin
antibody level assessment. Fisher’s exact test
was used to analyze binary data.
Relationships between UQMAPB status
(UQMAPB or not UQMAPB) and continuous
outcomes were analyzed by an analysis of
covariance model with adjustments for design
factors—with baseline HbA1c serving as a
covariate; and country, time of basal insulin
injection (daytime vs. evening/bedtime), sul-
fonylurea use (ELEMENT-2 only), treatment,
UQMAPB status, and treatment-by-UQMAPB
interaction as fixed effects. Relationships
between UQMAPB status and categorical out-
comes for adverse events were analyzed. The
Cochran–Mantel–Haenszel test was used for
between-treatment comparisons of odds ratios
within UQMAPB status subgroups. The
Breslow–Day test was used to assess the homo-
geneity of odds ratios for the interaction
between treatment and UQMAPB status. Data
were analyzed using SAS version 9.1.3 (SAS Drug
Development, Cary, NC, USA).
RESULTS
IAR Profiles of LY IGlar and IGlar
Treatment
Of the 535 patients with T1D (ELEMENT-1), 265
LY IGlar and 267 IGlar patients were evaluable.
Of the 756 patients with T2D (ELEMENT-2), 365
LY IGlar and 365 IGlar patients were evaluable.
No significant differences were observed in
either study between the medians for MAPB
levels for LY IGlar vs. IGlar or for the propor-
tions of patients in the respective UQMAPB
with either treatment (Table 1).
Relationship Between IAR and Clinical
and Safety Outcomes
There were no significant between-treatment
differences in baseline and endpoint values for
HbA1c, basal insulin dose, and body weight
among patients in UQMAPB or not in UQMAPB
(Table 2). Baseline-to-endpoint changes in
HbA1c and basal insulin dose were similar
between LY IGlar and IGlar irrespective of
UQMAPB status (Fig. 1a–d). While significant
treatment-by-UQMAPB interactions were noted
for the change from baseline to endpoint in total
(basal ? prandial) insulin dose (p = 0.008) and in
prandial insulin dose (p = 0.027) in ELEMENT-1,
therewere no significant treatment-by-UQMAPB
interactions for endpoint values of total insulin
dose (p = 0.105) or prandial insulin dose
(p = 0.143) in ELEMENT-1. More importantly
there were no between-treatment differences in
total insulin or in prandial insulin dose among
patients inUQMAPBornot inUQMAPB (Table 2)
which is consistent with the absence of
between-treatment differences in basal insulin
dose among patients by UQMAPB subgroups
(Fig. 1c, d). Although IGlar-treated patients who
demonstratedUQMAPB showed a greater weight
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gain than LY IGlar-treated patients or
IGlar-treated patients who exhibited lower
MAPB, this trendwas not found to be statistically
significant in either study (Fig. 1e, f).
In both studies, both treatment groups
exhibited similar frequencies of allergic reac-
tions, injection site reactions, and serious
adverse events irrespective of UQMAPB status
(Table 3). Likewise, the overall incidence of
hypoglycemia events was similar between both
treatment groups irrespective of patient
UQMAPB status (Fig. 2).
DISCUSSION
This study shows that patients with T1D or T2D
who received LY IGlar or IGlar exhibited similar
levels and frequencies of IARs. The number of
patients exhibiting IARs in the UQMAPB was
similar for LY IGlar and IGlar. Median antibody
levels of those patients in the UQMAPB were
comparable between both treatment groups and
low (i.e., less than 5%). No significant differen-
tial treatment effects were observed between LY
IGlar and IGlar for clinical efficacy or safety
outcomes among patients who did or did not
exhibit UQMAPBs for IARs. Clinical efficacy and
safety outcomes were similar among patients
treated with LY IGlar or IGlar regardless of IAR
levels.
LY IGlar has an identical primary amino
acid sequence, similar pharmacokinetic/phar-
macodynamic, efficacy, and safety profiles as
IGlar [4–6] and is considered a biosimilar
insulin in certain jurisdictions. In previous
studies, IGlar has been shown to exhibit a low
immunogenic potential compared to neutral
protamine Hagedorn (NPH) insulin. In a
28-week study that compared IGlar to NPH
insulin, 1–2% of patients with T1D in either
group exhibited clinically relevant [at least
20 U, % bound/total (B/T)] antibodies [16].
Similarly, IGlar was significantly less
immunogenic than NPH insulin in a 52-week
study of patients with T2D [17].
Table 1 Maximum antibody percent binding (MAPB) characteristics of evaluable patients
Outcome ELEMENT-1 (T1D) ELEMENT-2 (T2D)
LY IGlar IGlar LY IGlar IGlar
Evaluable patients, N 265 267 365 365
MAPB levels, % (n = 107) (n = 105) (n = 56) (n = 40)
Minimum 0.26 0.27 0.27 0.26
25th percentile 0.46 0.50 0.39 0.44
Mean (SD) 2.11 (3.71) 1.83 (3.15) 3.94 (7.75) 3.59 (5.78)
Median 0.84a 0.90a 0.56b 0.78b
75th percentile 2.13 1.66 3.29 3.90
Maximum 30.41 20.20 37.70 24.11
Patients in the upper quartile of MAPB, n (%) 29 (10.9)c 24 (9.0)c 14 (3.8)d 10 (2.7)d
Patients in the lower 3 quartiles of MAPB, n (%) 236 (89.1) 243 (91.0) 351 (96.2) 355 (97.3)
IGlar insulin glargine, LY IGlar LY2963016 insulin glargine, MAPB maximum antibody percent binding, SD standard
deviation, T1D type 1 diabetes, T2D type 2 diabetes
a Wilcoxon rank sum, p = 0.959
b Wilcoxon rank sum, p = 0.489
c Treatment comparison for the proportion of patients in the UQMAPB, p = 0.472
d Treatment comparison for the proportion of patients in the UQMAPB, p = 0.534
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Table 2 Baseline and endpoint values for HbA1c, insulin dose, and body weight by treatment-by-upper quartile of the
maximum antibody percent binding
UQMAPB–yes UQMAPB–no
LY IGlar IGlar p value LY IGlar IGlar p value
ELEMENT-1 (T1D)
Evaluable patientsa N = 265 N = 267 N = 265 N = 267








Baseline HbA1c (%) 7.71 (0.20) 7.84 (0.22) 0.663 7.75 (0.07) 7.78 (0.07) 0.722
Endpoint HbA1c (%) 7.58 (0.14) 7.62 (0.15) 0.834 7.49 (0.06) 7.48 (0.06) 0.844
Baseline basal insulin dose (U/kg/day) 0.36 (0.03) 0.31 (0.03) 0.277 0.32 (0.01) 0.31 (0.01) 0.305
Endpoint basal insulin dose (U/kg/day) 0.39 (0.03) 0.34 (0.03) 0.158 0.38 (0.01) 0.36 (0.01) 0.321
Baseline basal insulin lispro dose
(U/kg/day)
0.37 (0.04) 0.38 (0.04) 0.833 0.40 (0.01) 0.40 (0.02) 0.790
Endpoint basal insulin lispro dose
(U/kg/day)
0.45 (0.04) 0.38 (0.04) 0.181 0.36 (0.02) 0.37 (0.02) 0.530
Baseline total insulin dose (U/kg/day) 0.69 (0.05) 0.69 (0.05) 0.956 0.72 (0.02) 0.71 (0.02) 0.664
Endpoint total insulin dose (U/kg/day) 0.84 (0.05) 0.71 (0.06) 0.081 0.74 (0.02) 0.74 (0.02) 0.908
Baseline body weight (kg) 77.5 (3.0) 74.1 (3.3) 0.453 75.7 (1.05) 74.8 (1.0) 0.547
Endpoint body weight (kg) 77.6 (2.8) 72.2 (3.1) 0.179 74.2 (1.2) 73.3 (1.2) 0.506
ELEMENT-2 (T2D)
Evaluable patientsa N = 365 N = 365 N = 365 N = 365








Baseline HbA1c (%) 8.86 (0.29) 8.38 (0.34) 0.285 8.33 (0.06) 8.33 (0.06) 0.969
Endpoint HbA1c (%) 7.04 (0.24) 6.94 (0.28) 0.786 7.07 (0.07) 7.02 (0.07) 0.377
Baseline basal insulin dose (U/kg/day) 0.12 (0.06) 0.02 (0.08) 0.298 0.16 (0.01) 0.14 (0.01) 0.184
Endpoint basal insulin dose (U/kg/day) 0.52 (0.10) 0.51 (0.11) 0.921 0.50 (0.03) 0.48 (0.03) 0.437
Baseline body weight (kg) 79.9 (5.2) 84.9 (6.2) 0.540 90.8 (1.1) 90.3 (1.1) 0.744
Endpoint body weight (kg) 80.2 (5.1) 87.6 (5.9) 0.324 85.7 (1.4) 85.0 (1.4) 0.611
Data are least squares mean ± standard error
HbA1c glycated hemoglobin, IGlar insulin glargine, LY IGlar LY2963016 insulin glargine, UQMAPB upper quartile of
maximum antibody percent binding, T1D type 1 diabetes, T2D type 2 diabetes
a Deﬁned as patients having ‘‘detected’’ or ‘‘nondetected’’ insulin antibody levels at baseline and postbaseline visit (patients at











































































































































































































Our finding of no relationship between
immune response and efficacy or safety with LY
IGlar or IGlar is also consistent with previous
studies of IGlar. Although some of these studies
comparing IGlar and NPH insulin did not
specifically analyze any relationship between
anti-IGlar antibodies and clinical outcomes,
IGlar exhibited similar or greater glycemic
control than NPH [15–17]. In addition, treat-
ment-related adverse events were comparable
between IGlar and NPH insulin [17, 18]. A
recent retrospective analysis of seven published
registration studies that evaluated the
immunogenicity of IGlar and NPH in relation to
clinical outcomes found that the proportion of
patients with clinically relevant changes in
anti-IGlar antibody levels (at least 20 U, %B/T)
was low. In addition, antibody levels were not
associated with any clinically relevant effects on
HbA1c, insulin dose, and hypersensitivity [19].
Table 3 Treatment reactions and serious adverse events
UQMAPB–yes UQMAPB–no INT
p valuedLY IGlar IGlar p valueb LY IGlar IGlar p valuec
ELEMENT-1 (T1D)
Evaluable patientsa N = 265 N = 267 N = 265 N = 267








Allergic reactions, n (%) 2 (6.9) 1 (4.2) 0.672 18 (7.6) 10 (4.1) 0.102 0.927
Injection site reactions,
n (%)
0 (0.0) 0 (0.0) NA 7 (3.0) 3 (1.2) 0.186 NA
Serious adverse events
n (%)
3 (10.3) 1 (4.2) 0.401 17 (7.2) 23 (9.5) 0.372 0.282
ELEMENT-2 (T2D)
Evaluable patientsa N = 365 N = 365 N = 365 N = 365








Allergic reactions, n (%) 1 (7.1) 1 (10.0) 0.807 19 (5.4) 25 (7.0) 0.371 0.954
Injection site reactions,
n (%)
2 (14.3) 1 (10.0) 0.759 11 (3.1) 10 (2.8) 0.804 0.830
Serious adverse events
n (%)
0 (0.0) 0 (0.0) 14 (4.0) 17 (4.8) 0.604 NA
p values are not shown if the total number of patients with events for the combined subgroups and treatments is\10. If the
total number of events within a subgroup is 0, the interaction test is not performed. Patients may be counted in more than
one category of reaction or event
IGlar insulin glargine, INT interaction, LY IGlar LY2963016 insulin glargine, NA not assessed, T1D type 1 diabetes, T2D
type 2 diabetes, UQMAPB upper quartile of maximum antibody percent binding
a Deﬁned as patients having ‘‘detected’’ or ‘‘nondetected’’ insulin antibody levels at baseline and postbaseline visit (patients at
risk of treatment-emergent antibody response)
b p values are from the Mantel–Haenszel test for comparison of LY IGlar (yes) vs. IGlar (yes)
c p values are from the Mantel–Haenszel test for comparison of LY IGlar (no) vs. IGlar (no)
d Interaction p value assessed using the Breslow–Day test
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One study limitation is the sample size;
because the registration studies were originally
designed to demonstrate noninferiority in
HbA1c change [5, 6], some may argue that the
sample is relatively small to detect differences in
rare events, such as immune reactions. Notably,
the parent studies included 535 patients with
T1D and 756 patients with T2D, and the find-
ings in this study are consistent with what was
shown in analyses including the total study
populations [7]. Furthermore, no relationship
between UQMAPB status and clinical outcomes
was observed for patients with the highest IARs.
A second limitation is the study length which
limits our findings to anti-insulin antibody
formation for up to 24 or 52 weeks. However, it
should be noted that a previous 52-week study
has shown that the level of antibodies against
insulin glargine plateaus after approximately
20 weeks of treatment [17], a time frame cov-
ered by both studies in this analysis.
CONCLUSIONS
Patients treated with LY IGlar and IGlar had sim-
ilar maximum antibody responses, with similar
proportions of patients having high IARs. High
antibody levelswerenotassociatedwitheffectson
clinicaloutcomes.Thesefindings reduceconcerns
of immunogenicity responses that may affect
efficacyand safetywith insulinglargine treatment
and provide additional support for the similarity
between LY IGlar and IGlar.
Fig. 2 Overall incidence of hypoglycemia (blood glucose
no greater than 3.9 mmol/L) in patients with a type 1
diabetes (T1D) or b type 2 diabetes (T2D), hypoglycemia
(blood glucose less than 3.0 mmol/L) in patients with
c T1D or d T2D. IGlar insulin glargine, LY IGlar
LY2963016 insulin glargine, Pts patients, UQMAPB upper
quartile of maximum antibody percent binding
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